HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Principal findings from a multicenter trial investigating the safety of follicular-fluid meiosis-activating sterol for in vitro maturation of human cumulus-enclosed oocytes.

AbstractOBJECTIVE:
To evaluate the safety of applying follicular-fluid meiosis-activating sterol (FF-MAS) in vitro to immature human oocytes.
DESIGN:
Phase I bicenter, randomized, parallel-group, controlled, partially blinded trial.
SETTING:
Third-level referral academic centers, including reproductive biology and genetics laboratories.
PATIENTS:
Endocrinologically normal women with a medical indication for IVF or intracytoplasmic sperm injection, or healthy volunteers.
INTERVENTION(S):
Subjects were randomized at a ratio 1 to 6 into either conventional GnRH-agonist and recombinant FSH stimulation (IVO) for oocyte retrieval, or minimally stimulated in vitro maturation (IVM) with the use of recombinant FSH. Retrieved immature oocyte cumulus complexes were cultured for 30 or 36 hours in one of six IVM culture conditions containing FF-MAS (range, 0.1-20 microM). Polar body-extruded oocytes from the IVO and IVM groups were processed for chromosomal analysis.
MAIN OUTCOME MEASURE(S):
The primary endpoint was the incidence of metaphase II stage oocytes with numeric chromosomal abnormalities, using full (spectral karyotyping) or partial (fluorescent in situ hybridization with seven probes) karyotyping or Giemsa count. A secondary objective was to document the frequency of metaphase II oocytes after IVM with FF-MAS supplements.
RESULT(S):
Oocyte cumulus complexes obtained from the IVO (mean, 8.9) and IVM (mean, 6.2) groups had equal maturation rates. Compared to IVO, exposure of germinal-vesicle oocytes for a maturation period of 30 hours did not increase aneuploidy. An exposure period of 36 hours doubled the aneuploidy rate, but this was significant only for the 20-muM dose of FF-MAS.
CONCLUSION:
Inclusion of 1-10 microM FF-MAS in a 30-hour IVM protocol is safe.
AuthorsJohan Smitz, Helen-Mary Picton, Peter Platteau, Anthony Rutherford, Rita Cortvrindt, Julie Clyde, Daniela Nogueira, Paul Devroey, Karsten Lyby, Christian Gröndahl
JournalFertility and sterility (Fertil Steril) Vol. 87 Issue 4 Pg. 949-64 (Apr 2007) ISSN: 1556-5653 [Electronic] United States
PMID17198705 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Cholestenes
  • 4,4-dimethylcholesta-8,14,24-trienol
  • Follicle Stimulating Hormone
Topics
  • Adult
  • Aneuploidy
  • Cholestenes (adverse effects)
  • Chromosome Aberrations
  • Female
  • Fertilization in Vitro
  • Follicle Stimulating Hormone
  • Humans
  • In Vitro Techniques
  • Meiosis
  • Oocytes (drug effects, physiology, ultrastructure)
  • Sperm Injections, Intracytoplasmic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: